News & Views | Published:

Pancreatic cancer

Clinical practice guidelines — what is the evidence?

Nature Reviews Clinical Oncology volume 13, pages 593594 (2016) | Download Citation

In three practice guidelines from ASCO, experts provide evidence-based recommendations that address overarching clinical questions for the management of patients with pancreatic cancer. These guidelines offer improved strategies for interdisciplinary patient management and highlight the need for further research in several areas.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 2541–2556 (2016).

  2. 2.

    et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 2654–2668 (2016).

  3. 3.

    et al. Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. (2016).

  4. 4.

    et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155, 977–988 (2014).

  5. 5.

    et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br. J. Surg. 102, 1459–1472 (2015).

  6. 6.

    et al. Pancreatic cancer surgery: the new R-status counts. Ann. Surg. (2016).

  7. 7.

    et al. Adjuvant chemotherapy with fluorouracil plus folinic acid versus gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073–1081 (2010).

  8. 8.

    et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J. Clin. Oncol. Abstr. 34, aLBA4006 (2016).

  9. 9.

    et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann. Surg. 261, 961–969 (2015).

  10. 10.

    et al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th edition) changes for T and N staging in patients with pancreatic adenocarcinoma. Ann. Surg. (2016).

  11. 11.

    et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 17, 801–810 (2016).

  12. 12.

    et al. Locally advanced pancreatic cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients. Ann. Surg. (2016).

Download references

Author information

Affiliations

  1. Oliver Strobel and Markus W. Büchler are at the Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.

    • Oliver Strobel
    •  & Markus W. Büchler

Authors

  1. Search for Oliver Strobel in:

  2. Search for Markus W. Büchler in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Markus W. Büchler.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrclinonc.2016.127

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing